Business context and reporting period
The supplied Form 10-Q identifies the registrant as Owens & Minor, Inc., a medical and surgical supplies distributor and healthcare supply-chain services company—not Accendra Health Inc. It covers the quarter and six months ended June 30, 2012; the financial statements are unaudited. The company filed on July 27, 2012.
Financial results and position
Amounts below are in millions except per-share data. Year-over-year comparisons are against 2011.
| Metric | Q2 2012 | Q2 2011 | Six months 2012 | Six months 2011 |
|---|---|---|---|---|
| Revenue | $2,185.4 | $2,131.4 | $4,403.3 | $4,255.3 |
| Gross margin | $211.4 | $216.1 | $425.8 | $426.8 |
| Operating earnings | $53.2 | $51.0 | $105.0 | $102.0 |
| Net income | $30.1 | $29.2 | $59.5 | $57.9 |
| Diluted EPS | $0.48 | $0.46 | $0.94 | $0.91 |
| Gross margin rate | 9.67% | 10.14% | 9.67% | 10.03% |
| Operating margin | 2.43% | 2.39% | 2.39% | 2.40% |
- For the six months, operating cash flow was $142.8 million, investing cash flow was negative $18.0 million, and financing cash flow was negative $35.7 million. Cash increased $89.0 million to $224.9 million.
- At June 30, cash was $224.9 million; current assets were $1,531.4 million and current liabilities $707.8 million (current ratio about 2.16). Long-term debt, excluding current portion, was $212.0 million. The filing reports no revolver borrowings and $345 million available under the facility.
- Six-month capital expenditures were $18.2 million, including $12.7 million for software and intangible assets and $5.5 million for property and equipment. Dividends paid were $28.0 million; share repurchases were $7.5 million.
Material changes versus prior comparable periods
- Revenue rose 2.5% in Q2 and 3.5% for the first half. Q2 growth came chiefly from existing customers; net new/lost customer activity reduced revenue by $4.0 million. First-half net new customer activity added $29.1 million.
- Gross margin dollars declined 2.2% in Q2 and 0.3% for the first half, while gross margin rate fell 0.47 and 0.36 percentage points, respectively. Management attributed pressure primarily to customer mix—including lower-margin large integrated health network contracts—and competition.
- SG&A declined 3.9% in Q2 and 0.5% for the first half. Management cited cost reductions, the prior-year customer-conversion costs, and lower compensation, consulting, and outsourcing costs; higher warehouse and delivery costs partly offset these savings.
- Operating earnings increased 4.2% in Q2 and 3.0% for the first half; net income rose 3.3% and 2.7%, respectively. Management attributed earnings growth mainly to cost-reduction efforts and lower corporate-development expenses, partly offset by lower gross margin.
- First-half operating cash flow improved from $39.8 million to $142.8 million, principally reflecting lower inventory and receivables. Inventory fell to $748.8 million from $806.4 million at year-end; receivables fell to $485.2 million from $506.8 million. DSO improved to 19.5 days from 20.7 days.
Outlook, commentary, risks, and unusual items
- Management said available cash and financing sources should be sufficient for working capital, capital expenditures, strategic growth, debt and lease payments, dividends, and repurchases. It anticipated continuing quarterly dividends, subject to board discretion and business conditions. No specific earnings or revenue guidance was provided.
- A new five-year $350 million revolving credit agreement was signed June 5, 2012, replacing a facility due to expire in 2013. It matures in 2017, includes options for two one-year extensions and up to $150 million of additional commitments, and is subject to leverage and interest-coverage covenants. The company reported covenant compliance at quarter-end.
- On July 23, the company made a binding offer to acquire most of Celesio’s Movianto healthcare logistics business for approximately €130 million ($158 million), expected to close in Q3 subject to customary conditions. Management expected to use cash on hand. The offer was entered after quarter-end.
- On July 20, the company entered into Penske fleet lease and technology agreements. The lease schedules require about $63 million of minimum payments over seven years, subject to adjustments; the technology agreement calls for about $5 million over 36 months.
- Customer-contract performance contingencies totaled $4.2 million and were not accrued because management did not consider payment probable. Separately, a California review could yield a contingent tax incentive payment exceeding $7 million for prior periods; amount and timing were uncertain.
- Other noted exposures include customer credit and concentration, supplier funding and pricing, healthcare regulation, competition, fuel prices, acquisition integration, litigation, and access to financing. The filing estimates each 10-cent-per-gallon diesel benchmark change affects annual operating earnings by about $0.6 million before mitigation; approximately one-third of expected 2012 fuel use was under a fixed-price agreement.
- The company recorded a $0.2 million retirement-plan curtailment loss in the first half after freezing benefit levels and changing vesting provisions effective March 31. The filing reported no material legal-proceeding developments or material changes to previously disclosed risk factors.
Important facts for investors to verify
- Confirm the intended issuer: the supplied filing is for Owens & Minor, Inc., despite the request metadata naming Accendra Health Inc.
- Review the acquisition’s closing conditions, final consideration, funding, and subsequent integration costs for Movianto.
- Track gross-margin performance and the economics of lower-margin new customer contracts against the company’s cost savings.
- Assess the sustainability of the strong first-half operating cash flow, including inventory and receivables movements.
- Monitor the new credit facility’s covenant headroom and the incremental lease commitments under the Penske agreements.
- Follow the California tax incentive review and customer performance contingencies; neither potential receipt nor payment outcome was assured.